Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1995 2
1997 2
1998 1
1999 1
2007 2
2013 2
2014 2
2016 2
2017 5
2018 2
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Information et communication sur les risques liés au médicament et son bon usage auprès des professionnels de santé et du public : principe de précaution, gestion du risque, communication pendant et en dehors des situations de crise.
Molimard M, Bernaud C, Lechat P; et les participants à la table ronde N°6 de Giens XXIX :; Bejan-Angoulvant T, Benattia C, Benkritly A, Braunstein D, Cabut S, David N, Fourrier-Réglat A, Gallet B, Gersberg M, Goni S, Jolliet P, Lamarque-Garnier V, Le Jeunne C, Leurs I, Liard F, Malbezin M, Micallef J, Nguon M. Molimard M, et al. Among authors: malbezin m. Therapie. 2014 Jul-Aug;69(4):355-60. doi: 10.2515/therapie/2014044. Therapie. 2014. PMID: 27393228 French. No abstract available.
Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?
Lapeyre-Mestre M, Sapède C, Moore N; les participants à la table ronde N° 5 de Giens XXVIII :; Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: malbezin m. Therapie. 2013 Jul-Aug;68(4):241-6. doi: 10.2515/therapie/2013037. Therapie. 2013. PMID: 27392726 French. No abstract available.
Quelle pharmacovigilance pour les vaccins ?
Le Louët H, Loupi E, Haramburu F; participants de la table ronde n°3 de Giens XXII. Le Louët H, et al. Therapie. 2007 May-Jun;62(3):241-4. doi: 10.2515/therapie:2007048. Therapie. 2007. PMID: 27393409 French.
Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre M, Sapède C, Moore N; participants of round table N° 5 of Giens Workshops XXVIII (th); Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: malbezin m. Therapie. 2013 Jul-Aug;68(4):241-52. doi: 10.2515/therapie/2013038. Epub 2013 Aug 28. Therapie. 2013. PMID: 23981262 Free article. English, French.
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and OFSEP Investigators. Lebrun-Frénay C, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271. JAMA Netw Open. 2021. PMID: 34633424 Free PMC article.
Which Pharmacovigilance for Vaccines?
Le Louët H, Loupi E, Haramburu F; participants in Round Table N° 3, Giens XXII. Le Louët H, et al. Therapie. 2007 May-Jun;62(3):245-7. doi: 10.2515/therapie:2007039. Therapie. 2007. PMID: 27393410
22 results